【摘要】 目的:探讨经皮肝穿刺门静脉化疗栓塞治疗原发性肝癌门静脉癌栓的临床价值。方法:不能手术的伴门静脉癌栓的原发性肝癌45例,随机分成两组,研究组20例以TACE+PVE治疗,25例以单纯TACE治疗作为对照组,分别统计AFP的变化、门静脉癌栓缩小/消失的有效率以及1年生存率。结果:两组治疗前后AFP的变化:研究组(730±190)、(515±395)μg/L,对照组(752±183)、(710±213)μg/L,治疗后两组比较差异有显著性(P<0.05);两组门静脉癌栓缩小/消失率13/20(65%)、8/25(32%)(P<0.05);1年生存率15/20(75%)、12/25(48%)(P<0.05);两组均未见与治疗相关的严重副作用发生。结论:经皮肝穿刺门静脉化疗栓塞是治疗原发性肝癌门静脉癌栓的有效方法。更多还原

【Abstract】 Purpose:To assess the therapeutic value of perc utaneous portal vein chemoembolization (PVE) for primary hepatic carcinoma (PHC) with portal vein tumor thrombus. Methods:45 unresectable PHC with portal vein tumor thrombus cas es were randomly divided into two groups. The observation group was treated with transcatheter arterial chemoembolization (TACE)+PVE, while the control group wa s treated with TACE only. The changes of AFP, response rates of portal vein tumo r thrombus and survival rates of one year were analyzed respectively. Results:The levels of AFP before and after treatment were(730 ±190)μg/L and (515+±395)μg/L in the observation group,(752±183)μg/L a nd (710±213)μg/L in the control group respectively. The difference between t he two groups was significant (P<0.05). The reduction/disappearance rates of portal vein tumor thrombus were 13/20(65%) and 8/25(32%)(P<0.05). The 1-ye ar survival rates were 15/20(75%) and 12/25(48%)(P<0.05). There was no sever e side-effect related to therapy observed in both two groups. Conclusions:PVE is an effective method in the treatment of PHC with portal vein tumor thrombus.更多还原